Sai Parenteral's IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with strong capabilities in research, development, and manufacturing.The company operates through two primary business segments:Branded Generic FormulationsContract Development and Manufacturing…
Open Date
Tue, 24 Mar 2026
Close Date
Fri, 27 Mar 2026
Price Band
₹ 372 – 392
Lot Size
38
Issue Size
₹ 409.00 Cr
Minimum Investment
₹ 14,896 (38 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Sai Parenteral's IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹409.00 Crore, comprising a fresh issue of 72.70 Lakh equity shares aggregating to ₹285.00 Crore and an offer for sale (OFS) of 31.58 Lakh equity shares aggregating to ₹124.00 Crore by the existing shareholders.
The Sai Parenteral's IPO remained open for subscription from March 24, 2026, to March 27, 2026. The basis of allotment was finalized on March 30, 2026, and the company's shares were listed on the NSE and BSE on April 02, 2026.
The company had fixed the price band at ₹372 to ₹392 per share, with a lot size of 38 shares. Retail investors were required to make a minimum investment of ₹14,896 (based on the upper price band) to apply for one lot.
Bigshare Services Pvt Ltd served as the registrar to the issue. Arihant Capital Markets Ltd acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Sai Parenteral's Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Sai Parenteral's IPO Timeline (Tentative)
- IPO Open Date
- Tue, 24 Mar 26
- IPO Close Date
- Fri, 27 Mar 26
- Basis of Allotment
- Mon, 30 Mar 26
- Initiation of Refunds
- Wed, 01 Apr 26
- Credit of Shares to Demat
- Wed, 01 Apr 26
- Listing Date
- Thu, 02 Apr 26 — NSE & BSE
Open Date
24 March 2026
Close Date
27 March 2026
Basis Of Allotment
30 March 2026
Listing Date
02 April 2026
IPO Subscription
Check Live Subscription →The Sai Parenteral's IPO has received bids for 78,80,972 shares against 75,22,486 shares offered, resulting in an overall subscription of 1.05x. the NII category is subscribed 2.36x, Retail Investors 0.12x, and QIBs 1.71x. Within the NII category, BNII is subscribed 3.43x, while SNII is subscribed 0.23x.
QIB
1.71x
NII
2.36x
BNII
3.43x
SNII
0.23x
RII
0.12x
Total
1.05x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 37,86,710 shares, representing 50.34% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 21,12,900 shares (28.09%), while Non-Institutional Investors (NIIs) receive 16,22,876 shares (21.57%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 2,112,900 | 28.09% |
| Non-Institutional | 1,622,876 | 21.57% |
| BNII | 1,081,918 | 14.38% |
| SNII | 540,958 | 7.19% |
| Retail Investors | 3,786,710 | 50.34% |
| Total | 7,522,486 | 100% |
Financials Details(₹ in Crores)
| Particular | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.1 | 133.96 |
| Revenue | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| Net Worth | 209.37 | 95.78 | 76.4 | 31.49 |
| Reserve & Surplus | 188.84 | 80.36 | 61.3 | 24.34 |
| Total Borrowings | 76.07 | 93.95 | 118.79 | 68.55 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Sai Parenteral's Limited KPI Information
| Particular | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 5.13 | 16.82 | 15.67 | 15.75 |
| ROCE % | 9.28 | 28.92 | 20.52 | 21.04 |
| RoNW % | 5.09 | 15.09 | 11.01 | 13.9 |
| Pat Margin % | 8.93 | 8.88 | 5.47 | 4.52 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Sai Parenteral's Ltd | 5 | 0.00 | 5.43 | 5.43 | 15.09 | 35.98 |
| Sai Life Sciences Ltd | 1 | 107.70 | 8.83 | 8.61 | 7.99 | 102.12 |
| Innova Captab Ltd | 10 | 32.45 | 22.41 | 22.41 | 13.37 | 167.66 |
| Senores Pharmaceutic als Ltd | 10 | 64.30 | 16.12 | 16.12 | 7.18 | 176.37 |
| Gland Pharma Ltd | 1 | 44.71 | 42.40 | 42.40 | 7.63 | 555.41 |
About Sai Parenteral's Limited
Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with strong capabilities in research, development, and manufacturing.
The company operates through two primary business segments:
- Branded Generic Formulations
- Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets
Sai Parenteral’s offers a broad product portfolio across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Its products are available in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company serves a diverse customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists across India.
In FY 2023, Sai Parenteral’s expanded into international markets following the acquisition of two internationally accredited manufacturing facilities in Hyderabad, Telangana. It now exports to regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Sai Parenteral’s operates five manufacturing facilities in India. Four of these are located in Hyderabad, Telangana, including:
- A GMP-compliant injectable unit
- A WHO-GMP certified injectable unit
- A TGA (Australia) and PIC/S accredited solid oral dosage facility
- A WHO-GMP certified cephalosporin unit
Additionally, its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified manufacturing facility in Ongole, Andhra Pradesh.
As of August 31, 2025, the company employed 277 full-time staff members.
Sai Parenteral's IPO Promoters
- Anil Kumar Karusala
- Vijitha Gorrepati
- Karusala Aruna
Promoters Holding
Holding Pre Issue
61.23%
Holding Post Issue
0.00%
Sai Parenteral's IPO Objective
The Company Sai Parenteral's IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Capacity expansion and upgradation of manufacturing facilities
- Establishment of a new R&D centre
- Repayment / prepayment of certain outstanding borrowings
- Working capital requirements
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
- General corporate purposes
Sai Parenteral's Limited Address / Contact Details
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
IPO Snapshot
Sai Parenteral's IPO Lot Size
The Sai Parenteral's IPO has a lot size of 38 shares. Retail investors require a minimum investment of ₹14,896 by applying for 1 lot (38 shares). The maximum application allowed for the retail category is 13 lots (494 shares), requiring an investment of ₹1,93,648.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 14,896.00 |
| Retail (Max) | 13 | 494 | 193,648.00 |
| S-HNI (Min) | 14 | 532 | 208,544.00 |
| S-HNI (Max) | 67 | 2,546 | 998,032.00 |
| B-HNI (Min) | 68 | 2,584 | 1,012,928.00 |
Issue Reservation
- QIB — 28.09%
- NII — 21.57%
- RII — 50.34%
Book Running Lead Managers
- Arihant Capital Markets Ltd
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Sai Parenteral's IPO?
Sai Parenteral's IPO is a Book-building IPO with a total issue size of ₹409 crore. The Sai Parenteral's IPO price band is ₹372 to 392 per share. The Sai Parenteral's IPO subscription opens on Tue, Mar 24, 2026, and closes on Fri, Mar 27, 2026. The Sai Parenteral's IPO will be listed on the BSE,NSE. Bigshare Services Pvt Ltd is the registrar for the Sai Parenteral's IPO.
When will the Sai Parenteral's IPO open for subscription?
The Sai Parenteral's IPO opens on Tue, Mar 24, 2026 and closes on Fri, Mar 27, 2026
What is Sai Parenteral's IPO Price Band?
Sai Parenteral's IPO Price Band is ₹372 to 392 per share.
What is Sai Parenteral's IPO Lot Size?
Sai Parenteral's IPO lot size is 38 shares, Retail investors need a minimum investment of ₹14896 based on the upper price band
What is the minimum investment for Sai Parenteral's IPO?
The minimum investment for Sai Parenteral's IPO is ₹14896, based on one lot of 38 shares at the upper price band of ₹392 per share.
How to apply for Sai Parenteral's IPO?
Investors can apply for the Sai Parenteral's IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Mar 27, 2026. The application amount remains blocked until the Sai Parenteral's IPO allotment is finalized.
What is Sai Parenteral's IPO Issue Size?
Sai Parenteral's IPO issue size is ₹409 crores.
What is the Sai Parenteral's IPO Allotment Date?
Sai Parenteral's IPO allotment date is Mon, Mar 30, 2026.
Who is the Sai Parenteral's IPO Registrar?
The registrar for Sai Parenteral's IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Sai Parenteral's IPO allotment status, refund processing, and other IPO-related information.
Who is the Sai Parenteral's IPO Lead Manager?
The book-running lead managers (BRLMs) for the Sai Parenteral's IPO are Arihant Capital Markets Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Sai Parenteral's IPO Red Herring Prospectus (RHP).